Synapse - Naiyer Rizvi

Results (166)

Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2

Meeting Abstract

Rizvi, N. A.; Kris, M. G.; Miller, V. A.; Krug, L. M.; Bekele, S.; Dowlati, A.; Rowland, K. M.; Salgia, R.; Aggarwal, N.; Gadgeel, S. M.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Pack years of cigarette smoking as a predictor of survival in 2,013 patients with stage IIIb/IV non-small cell lung cancer (NSCLC)

Meeting Abstract

Janjigian, Y. Y.; McDonnell, K.; Kris, M. G.; Shen, R.; Sima, C. S.; Rizvi, N. A.; Riely, G. J.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Analysis of EGFR and KRAS mutations in circulating tumor DNA (cTDNA) from plasma of NSCLC patients in phase 2 trials of XL647

Meeting Abstract

Schimmolle, F.; Rizvi, N. A.; Vysotskaia, V. S.; Funke, R. P.; Dixon, S.; Buller, R. E.
EJC Supplements (2008)

Fulltext@MSK | Save

Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer

Journal Article

Rizvi, N. A.; Riely, G. J.; Azzoli, C. G.; Miller, V. A.; Ng, K. K.; Fiore, J.; Chia, G.; Brower, M.; Heelan, R.; Hawkins, M. J.; more...
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer

Meeting Abstract

Riely, G. J.; Rudin, C. M.; Kris, M. G.; Senturk, E.; Azzoli, C. G.; Brahmer, J.; Fogle, M.; Ginsberg, M.; Miller, V. A.; Rizvi, N. A.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer

Meeting Abstract

Rizvi, N. A.; Rusch, V.; Zhao, B.; Senturk, E.; Schwartz, L.; Fury, M.; Downey, R.; Rizk, N.; Krug, L.; Kris, M. G.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

A phase II study to determine if sensory neuropathy of nab-paclitaxel can be reduced by prolonging infusion in patients with non-small cell lung cancer (NSCLC)

Meeting Abstract

James, L. P.; Kris, M. G.; Heelan, R. T.; Ng, K. K.; Chia, G. H.; Gomez, J. E.; Krug, L. M.; Moore, E.; Hawkins, M. J.; Rizvi, N. A.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations

Meeting Abstract

Rizvi, N.; Kris, M.; Miller, V.; Krug, L.; Bekele, S.; Dowlati, A.; Rowland, K.; Tonda, M.; Mitchell, B.; Ruckdeschels, J.; more...
Molecular Cancer Therapeutics (2007)

Fulltext@MSK | Save

Prospective trial of preoperative gefitinib to correlate response with EGFR exon 19 and 21 mutations and to select patients for adjuvant gefitinib